Sam Chun Dang Pharm Co Ltd banner
S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 411 500 KRW 8.29% Market Closed
Market Cap: ₩9.7T

Sam Chun Dang Pharm Co Ltd
Net Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sam Chun Dang Pharm Co Ltd
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Net Income
₩12B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
-4%
Yuhan Corp
KRX:000100
Net Income
₩185.3B
CAGR 3-Years
27%
CAGR 5-Years
-1%
CAGR 10-Years
4%
SK Biopharmaceuticals Co Ltd
KRX:326030
Net Income
₩253.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Net Income
₩187.1B
CAGR 3-Years
23%
CAGR 5-Years
61%
CAGR 10-Years
1%
M
Mezzion Pharma Co Ltd
KOSDAQ:140410
Net Income
-₩34.9B
CAGR 3-Years
1%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
C
Caregen Co Ltd
KOSDAQ:214370
Net Income
₩20.1B
CAGR 3-Years
-10%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
9.7T KRW
Industry
Pharmaceuticals

Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets. The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.

Intrinsic Value
8 992.31 KRW
Overvaluation 98%
Intrinsic Value
Price ₩411 500
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Net Income?
Net Income
12B KRW

Based on the financial report for Dec 31, 2025, Sam Chun Dang Pharm Co Ltd's Net Income amounts to 12B KRW.

What is Sam Chun Dang Pharm Co Ltd's Net Income growth rate?
Net Income CAGR 10Y
-4%

The average annual Net Income growth rates for Sam Chun Dang Pharm Co Ltd have been 11% over the past three years , 10% over the past five years , and -4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett